Neutrophil cytosolic factor 2 (NCF2) (NCF2)

Neutrophil cytosolic factor 2 (NCF2), also known as p67-phox, is a critical cytosolic subunit of the multi-protein NADPH oxidase complex found primarily in phagocytes (UniProt P19878). Upon cell activation, NCF2 translocates from the cytosol to the plasma membrane, where it interacts with other subunits like p47-phox and cytochrome b-245 to initiate the production of superoxide anions (PubMed: 25223444). This process, known as the respiratory burst, is essential for the microbicidal activity of neutrophils and macrophages during the innate immune response (NIH: Gene ID 4688). Mutations in the NCF2 gene are a known cause of autosomal recessive chronic granulomatous disease (CGD), a condition characterized by recurrent life-threatening bacterial and fungal infections due to the inability of phagocytes to kill pathogens (PubMed: 23434371). Additionally, genetic variants in NCF2 have been associated with an increased risk of systemic lupus erythematosus (SLE), suggesting its role in maintaining immune tolerance (PubMed: 21841781). While there are currently no FDA-approved small molecules that specifically target NCF2, it is a primary focus for gene therapy clinical trials aimed at restoring NADPH oxidase function in CGD patients (PubMed: 31917643). Research also explores the modulation of NCF2-mediated ROS production to treat inflammatory and autoimmune disorders (PubMed: 28611154).

Other names

p67-phoxP67PHOXNOXA2Neutrophil NADPH oxidase factor 2

Activation of the NADPH oxidase complex to catalyze the reduction of oxygen to superoxide; Gene replacement therapy to restore enzyme function